PHARMA MAR, S.A. «12» Page 2 out of 2 23/04/2020 17:38 PHARMA MAR, S.A. On P&L The Company sends press release regarding the Q1 2020 results Register number: 178 20/04/2020 14:34 PHARMA MAR, S.A. On credit ratings Axesor raises long-term credit rating of Pharma Mar. Register number: 167 25/03/2020 17:42 PHARMA MAR, S.A. On share buy-back , stabilisation and treasury stock programmes The Company reports that it will carry out a program to buy-back treasury shares Register number: 113 13/03/2020 08:30 PHARMA MAR, S.A. On business and financial situation The Company reports the in vitro studies results of Aplidin® (plitidepsin) on the human coronavirus HCoV-229E Register number: 90 Related to communication no. 82 dated 03/03/2020 (14:49) 06/03/2020 14:18 PHARMA MAR, S.A. On business and financial situation The Company reports that its subsidiary Genomica, S.A.U. has obtained today the “CE” conformity marking of its COVID-19 coronavirus diagnostic kits. Register number: 83 03/03/2020 14:49 PHARMA MAR, S.A. On business and financial situation The Company reports that it has a therapeutic compound, Aplidin, which by its mechanism of action could be effective in treating the current outbreak of coronavirus, called Covid-19. Register number: 82 17/02/2020 08:28 PHARMA MAR, S.A. On business and financial situation Pharma Mar reports that the FDA has accepted and granted priority review to its New Drug Application for lurbinectedin under accelerated approval for the treatment of small-cell lung cancer. Register number: 15 Page 2 out of 2 «12»